Advocacy in Action: July 2

July 2, 2024
 
  

What's happened

Ongoing, Health Canada Drug Shortages Meetings

Through participation at these meetings, CSHP is continuing to monitor these ongoing drug shortages 
  • June 17 Tier Assignment Committee: Shortages of Pantoprazole Injection  
  • June 19 Tier Assignment Committee: Shortages of Epinephrine Injection Prefilled Syringes 
  • June 20 Tier Assignment Committee De-escalation: De-escalation of Potassium Chloride for injection 
  • June 26: Discontinuation of Zovirax (acyclovir) Suspension  

June 19, GS1 Canada Pharmacy Deployment Committee Meeting 

CSHP has joined GS1 Canada’s Pharmacy Deployment Committee. This collaboration aims to promote global standards-based practices and peer-to-peer sharing within the pharmacy community, focusing on accurately identifying medications throughout the supply chain through automation and global standards adoption.

What's happening

June to July, NAPRA Consultation on Modernization of Drug Schedules

CSHP will be wrapping up a consultation on two of NAPRA’s potential models for non-prescription drug (NPD) scheduling and their respective terms of sale for inclusion in the updated program. Thank you to all members who have offered their insight on these topics.

June to July, Health Canada Consultation on Controlled Drugs and Substances Act

CSHP is  drafting a response to a Health Canada consultation on the proposed Controlled Substances Regulations and related amendments to other federal regulations, including the Cannabis Regulations, as published in the Canada Gazette, Part I. Outreach for input from Branches and Members at-large on this consultation is currently in progress.

July, Health Canada Consultation on Food and Drug Regulations and the Medical Devices Regulations

Health Canada recently released Building resilience: Health Canada’s plan to address health product shortages, 2024 to 2028. This publication is a result of extensive public and stakeholder consultations in 2023 and outlines their proposed regulatory and non-regulatory actions they will be taking to mitigate and prevent shortages of drugs and medical devices over the next four years.  

As a result, they will be making amendments to Food and Drug Regulations and the Medical Devices Regulations and have asked CSHP to consult on their proposed amendments. CSHP National is drafting a response and will seek input from Branches and Members at-large on this consultation prior to submission. 

What's worth repeating

June 12, Multilateral Meeting with Health Canada 

CPO Rita Dhami participated in a multilateral meeting with Health Canada. While in attendance, she received updates from the various divisions of Health Canada including the Marketed Health Products Branch, the Pharmaceutical Drugs Directorate, the Health Product Compliance Directorate, and the Biologic and Radiopharmaceutical Directorate as well as some policy updates. 


To catch up on CSHP advocacy news, click here.

Have a question about Advocacy in Action or CSHP's advocacy and consultation work?
Reach out to our professional practice team!